Caladium Seguinum 3 X Drops ; Globules ; Granules ; Liquid ; Pellet ; Tablet is a Health Canada–registered human drug (DIN 02233740) held by Seroyal International Inc., containing Caladium Seguinum. Health Canada lists its status as Cancelled Post Market (status date 06 Jul 2009). Nexara Health has matched 11 registrations of Caladium Seguinum across 2 other regulated markets.
Health Canada registration
| DIN | 02233740 |
|---|---|
| Brand name | Caladium Seguinum |
| Active ingredient | Caladium Seguinum |
| Strength | 3 X |
| Dosage form | Drops ; Globules ; Granules ; Liquid ; Pellet ; Tablet |
| Route | Oral |
| Company | Seroyal International Inc. |
| Status | Cancelled Post Market — 06 Jul 2009 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Caladium Seguinum registered in other markets
11 registrations of the same molecule in 2 national registries outside Canada (first 10 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Netherlands | Caladium seguinum | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Uitsluitend apotheek of drogist | EU national register | |
| Netherlands | Caladium seguinum | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Globuli | Uitsluitend apotheek of drogist | EU national register |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Caladium Seguinum | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC |
See every manufacturer of Caladium Seguinum worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Caladium Seguinum (DIN 02233740) marketed in Canada?
No. Health Canada lists DIN 02233740 as Cancelled Post Market as of 06 Jul 2009.
Who holds the Canadian licence for this product?
Seroyal International Inc. is the company of record in the Health Canada Drug Product Database.
Is Caladium Seguinum registered outside Canada?
Yes — Nexara Health has matched 11 registrations in 2 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02233740, status date 2009-07-06; national medicine registries: EU national register, FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02233740, status date 2009-07-06; national medicine registries: EU national register, FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02233740, status date 2009-07-06; national medicine registries: EU national register, FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.